Colitis

Aug 09, 2017

InDex Pharmaceuticals Receives Orphan-drug Designation for Pediatric Ulcerative Colitis in the US

Aug 03, 2017

Ulcerative Colitis Therapeutics Pipeline Analysis 2017: Approximately 89 Drug Candidates in Different Stages of Development

Aug 02, 2017

TARGET PharmaSolutions Enrolls First Participant in its Inflammatory Bowel Disease (IBD) Community

Jun 21, 2017

InDex Pharmaceuticals Enrolls First Patient in the Phase IIb Study CONDUCT With Cobitolimod

Jun 13, 2017

TECHLAB® Receives FDA 510(k) Clearance To Market E. HISTOLYTICA QUIK CHEK(TM) To Aid Clinicians In The Diagnosis Of Amebiasis Caused By The E. Histolytica Parasite